ReviewVascular health and risk management2008
High density lipoprotein cholesterol: an evolving target of therapy in the management of cardiovascular disease.
Review in Vascular health and risk management, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 65 citations in OpenAlex.
- The effects of fenofibrate on inflammation and cardiovascular markers in patients with active rheumatoid arthritis: a pilot study.Rheumatology international · 2013Trial
- The impact of a disease management program (COACH) on the attainment of better cardiovascular risk control in dyslipidaemic patients at primary care centres (The DISSEMINATE Study): a randomised controlled trial.BMC family practice · 2012Trial
- Multi-pronged molecular insights into flavonoid-mediated inhibition of squalene epoxidase: a pathway to novel therapeutics.RSC advances · 2025Article
- High density lipoprotein: When to rethink too much of a good thing.American journal of preventive cardiology · 2023Article
- In Vitro and In Vivo Toxicological Evaluation ofJournal of toxicology · 2022Article
- Antidyslipidemic Potential of Water-Soluble Polysaccharides ofEvidence-based complementary and alternative medicine : eCAM · 2021Article
- The relationship between plasma lipids, oxidant-antioxidant status, and glycated proteins in individuals at risk for atherosclerosis.Clinical interventions in aging · 2019Article
- Tangier disease may cause early onset of atherosclerotic cerebral infarction: A case report.Medicine · 2018Article
- Using Zebrafish for High-Throughput Screening of Novel Cardiovascular Drugs.JACC. Basic to translational science · 2017Review
- Beta-Glucan-Rich Extract from Pleurotus sajor-caju (Fr.) Singer Prevents Obesity and Oxidative Stress in C57BL/6J Mice Fed on a High-Fat Diet.Evidence-based complementary and alternative medicine : eCAM · 2013Article
- HDL mimetics inhibit tumor development in both induced and spontaneous mouse models of colon cancer.Molecular cancer therapeutics · 2012Article
- High Density Lipoprotein and it's Dysfunction.The open biochemistry journal · 2012Article
- The Scl1 of M41-type group A Streptococcus binds the high-density lipoprotein.FEMS microbiology letters · 2010Article
- Plasma Protein Biomarkers Correlated with the Development of Diet-Induced Type 2 Diabetes in Mice.Clinical proteomics · 2010Article
- Extracellular hydrophobic regions in scavenger receptor BI play a key role in mediating HDL-cholesterol transport.Archives of biochemistry and biophysics · 2010Article
- The ectopic F(O)F(1) ATP synthase of rat liver is modulated in acute cholestasis by the inhibitor protein IF1.Journal of bioenergetics and biomembranes · 2010Article
- The link between human and transgenic animal studies involving postprandial hypertriglyceridemia and CETP gene polymorphisms.The open cardiovascular medicine journal · 2009Article
- Beta-glucans in the treatment of diabetes and associated cardiovascular risks.Vascular health and risk management · 2008Review
- Predictive and Prognostic Value of High-density Lipoprotein Cholesterol in Young Male Patients with Acute Myocardial Infarction.Chinese medical journalArticle
- Emerging LDL therapies: Using human genetics to discover new therapeutic targets for plasma lipids.Journal of clinical lipidologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Since the pioneering work of John Gofman in the 1950s, our understanding of high density lipoprotein cholesterol (HDL-C) and its relationship to coronary heart disease (CHD) has grown substantially. Numerous clinical trials since the Framingham Study in 1977 have demonstrated an inverse relationship between HDL-C and one's risk of developing CHD. Over the past two decades, preclinical research has gained further insight into the nature of HDL-C metabolism, specifically regarding the ability of HDL-C to promote reverse cholesterol transport (RCT). Recent attempts to harness HDL's ability to enhance RCT have revealed the complexity of HDL-C metabolism. This review provides a detailed update on HDL-C as an evolving therapeutic target in the management of cardiovascular disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.